A model of the endogenous glucose balance incorporating the characteristics of glucose transporters

Arleth, Tom; Andreassen, Steen; Federici, Marco Orsini; Benedetti, M. Massi

doi:10.1016/s0169-2607(00)00069-9

Cited by 32 publications

(46 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The MM is well documented and used (Pacini et al, 1986). The RM model was developed for a Type 1 diabetes decision support system (Arleth et al, 2000).…”

Section: Receptor Model (Rm)mentioning

confidence: 99%

“…However, only a few clinically validated models can predict within clinically acceptable ranges (e.g. Wong et al, 2006;Lotz et al, 2006;Arleth et al, 2000;Hovorka et al, 2004). This paper presents a new form of model validation, by examining the steady state pharmaco-dynamic (PD) surfaces, including underlying pharmaco-kinetics (PK).…”

Section: Introductionmentioning

confidence: 99%

“…This paper presents a new form of model validation, by examining the steady state pharmaco-dynamic (PD) surfaces, including underlying pharmaco-kinetics (PK). A 3D surface of plasma insulin (x), plasma glucose (y) and resulting rate of change in endogenous glucose balance (z) is compared to 77 sets of glycaemic clamp data (Arleth et al, 2000), creating a new form of clinical model validation in the comparison.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Glucose-Insulin Pharmacodynamic Surface Modeling Comparison

Chase

Andreassen

Pielmeier

et al. 2008

IFAC Proceedings Volumes

Self Cite

View full text Add to dashboard Cite

Metabolic system modeling for use in glycaemic control is increasing in importance. Few models are clinically validated for both fit and prediction ability. For such models, this research introduces a new form of pharmaco-dynamic (PD) surface comparison for model validation. These 3D surfaces are developed for 3 validated models, including the well-known Minimal Model, and fit to clinical data. The approach is clearly highlights differences in modeling methods, dynamics utilized and physiological assumptions that may not appear as clearly in other validation approaches. The deficiencies of the Minimal Model in comparison to more physiologically representative models are illustrated in this context.

show abstract

“…The MM is well documented and used (Pacini et al, 1986). The RM model was developed for a Type 1 diabetes decision support system (Arleth et al, 2000).…”

Section: Receptor Model (Rm)mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Glucose-Insulin Pharmacodynamic Surface Modeling Comparison

Chase

Andreassen

Pielmeier

et al. 2008

IFAC Proceedings Volumes

Self Cite

View full text Add to dashboard Cite

show abstract

“…This article compares the simple Minimal Model against the existing DISST model and a modified DISST model that includes a term for glomerular filtration (kidney clearance of glucose) which occurs at high glucose concentrations (Arleth et al 2000, Rave et al 2006. The added glomerular filtration term used here is derived from the model of (Arleth et al 2000).…”

Section: Introductionmentioning

confidence: 99%

“…The added glomerular filtration term used here is derived from the model of (Arleth et al 2000). The models are presented in Equations (1) …”

Section: Introductionmentioning

confidence: 99%

Evaluation of a Glomerular Filtration Term in the DISST Model to Capture the Glucose Pharmacodynamics of an Insulin-Resistant Cohort.

Docherty

Chase

Lotz

et al. 2011

IFAC Proceedings Volumes

View full text Add to dashboard Cite

Glomerular filtration (kidney clearance) of glucose occurs at high glucose concentrations. Thus, the applicability of glomerular filtration terms in models of insulin and glucose pharmacodynamics (PD) should be investigated.To evaluate such a term, data from 36 insulin sensitivity tests on 12 participants with type 2 diabetes in an Atkins diet intervention study was analysed using three PD models. The models include the dynamic insulin sensitivity and secretion test (DISST) model the DISST model with an added glomerular filtration rate (GFR) term and the well-known Minimal Model (MM). The identified insulin sensitivity values and simulation fit-to-data residuals are analysed to test performance and differences.The Minimal Model produced the best fit-to-data with a median residual of 0mmol/L and IQR of -0.13, 0.18mmol/L. Both DISST models also produced residuals with a median of 0mmol/L but an IQR of approximately -0.41, 0.37mmol/L. However, the DISST derived sensitivity values were considerably more in accordance with expected trends, showing the expected 20-50% increase in sensitivity for most subjects due to the intervention. In contrast, the Minimal Model repeated the variable trade-off issue previously recorded for this model with insulin resistant participants. The Minimal Model sensitivity values were effectively random, and did not capture observable changes in insulin sensitivity of glucose clearance.The addition of a GFR term had a positive impact on the identified insulin sensitivity by shifting some values more toward expected and observable behaviour. However, more data must be made available for an exhaustive investigation of the applicability of this term for this type of usage.

show abstract

Model-Based Medical Decision Support for Glucose Balance in ICU Patients: Optimization and Analysis

Cibis

Marheineke

2014

Mathematics in Industry

View full text Add to dashboard Cite

A model of the endogenous glucose balance incorporating the characteristics of glucose transporters

Cited by 32 publications

References 34 publications

Glucose-Insulin Pharmacodynamic Surface Modeling Comparison

Glucose-Insulin Pharmacodynamic Surface Modeling Comparison

Evaluation of a Glomerular Filtration Term in the DISST Model to Capture the Glucose Pharmacodynamics of an Insulin-Resistant Cohort.

Model-Based Medical Decision Support for Glucose Balance in ICU Patients: Optimization and Analysis

Contact Info

Product

Resources

About